Ads
related to: cure for glaucoma soon says new research article on cancer risk calculator
Search results
Results from the WOW.Com Content Network
Glaucoma is a group of diseases affecting the optic nerve that results in vision loss and is frequently characterized by raised intraocular pressure (IOP). There are many glaucoma surgeries, and variations or combinations of those surgeries, that facilitate the escape of excess aqueous humor from the eye to lower intraocular pressure, and a few ...
Corticosteroid-induced glaucoma: Corticosteroids is a risk factor for the development of secondary glaucoma, as there had been increased IOP observed as a drug side-effect. [2] Post-traumatic glaucoma: Trauma to the eye is often observed to cause secondary glaucoma.
For individual men, the discriminatory accuracy [5] for colon cancer was 0.71 and for pancreatic cancer was 0.72. These values exceed the performance of many other cancer risk prediction tools. [6] [7] The approach used to calculate cancer risks in Your Disease. Risk is also used to calculate the risks of the other diseases. [8]
Novartis' eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans ...
In acute angle-closure glaucoma cases, surgical iridectomy has been superseded by Nd:YAG laser iridotomy, because the laser procedure is much safer. Opening the globe for a surgical iridectomy in a patient with high intraocular pressure greatly increases the risk of suprachoroidal hemorrhage, with potential for associated expulsive hemorrhage.
The result is a lifetime risk and a five-year risk based on factors that have been tied to a higher risk of breast cancer. For comparison, it also gives an average risk for U.S. women of the same ...
Research to suss out exactly how obesity might contribute to or cause cancer is ongoing, but there are some leading theories, Timothy Rebbeck, professor of cancer prevention at the Dana-Farber ...
The Hydrus Microstent is an implantable MIGS device for the treatment of primary open angle glaucoma; implantation of this device can be performed in conjunction with cataract surgery. [30] The Hydrus Microstent is the longest of the MIGS devices (8-millimeter long implant), and similar to the iStent it is designed to increase trabecular outflow.
Ads
related to: cure for glaucoma soon says new research article on cancer risk calculator